Copyright © 2004 American Medical Association. All rights reserved. From: Treatment of the Patient With Diabetes Mellitus and Risk of NephropathyWhat Do We Know, and What Do We Need to Learn? Arch Intern Med. 2004;164(2):125-130. doi:10.1001/archinte.164.2.125 Figure Legend: Studies of treatment effect (angiotensin-converting enzyme [ACE] inhibitor and angiotensin II receptor blocker [ARB] trials) on risk of progression to macroalbuminuria, compared with fixed-effects and random-effects models. Because the estimate of between-study variance was zero for progression to macroalbuminuria, the fixed-effects model was the same as the random-effects model (P>.5 for heterogeneity). Error bars represent 95% confidence intervals. (Confidence interval was not available for Irbesartan Diabetic Nephropathy Trial [IDNT].) IMSG indicates Italian Microalbuminuria Study Group; IDDM, insulin-dependent diabetes mellitus; EUCLID, EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes; MDNSG, Melbourne Diabetic Nephropathy Study Group; ESPRIT, European Study of the Progression of Renal Disease in Type 1 Diabetes; PRIMA, Project With Ramipril on Insulin Dependent Patients With Microalbuminuria; and ATLANTIS, ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects. Adapted with permission from the ACE Inhibitors in Diabetic Nephropathy Trialist Group. Date of download: 12/25/2017 Copyright © 2004 American Medical Association. All rights reserved.

Copyright © 2004 American Medical Association. All rights reserved. From: Treatment of the Patient With Diabetes Mellitus and Risk of NephropathyWhat Do We Know, and What Do We Need to Learn? Arch Intern Med. 2004;164(2):125-130. doi:10.1001/archinte.164.2.125 Figure Legend: Studies of treatment effect (angiotensin-converting enzyme [ACE] inhibitor and angiotensin II receptor blocker [ARB] trials) on regression to normoalbuminuria, compared with fixed-effects and random-effects models. Because the estimate of between-study variance was zero for progression to macroalbuminuria, the fixed-effects model was the same as the random-effects model (P>.5 for heterogeneity). Error bars represent 95% confidence intervals. (Confidence intervals were not available for MicroAlbuminuria Reduction With VALsartan [MARVAL] and Irbesartan Diabetic Nephropathy Trial [IDNT].) IMSG indicates Italian Microalbuminuria Study Group; IDDM, insulin-dependent diabetes mellitus; EUCLID, EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes; MDNSG, Melbourne Diabetic Nephropathy Study Group; ESPRIT, European Study of the Progression of Renal Disease in Type 1 Diabetes; and ATLANTIS, ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects. Adapted with permission from the ACE Inhibitors in Diabetic Nephropathy Trialist Group. Date of download: 12/25/2017 Copyright © 2004 American Medical Association. All rights reserved.